Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human ...
The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities ...
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at ...
Members of the FDA’s Oncologic Drugs Advisory Committee questioned AstraZeneca’s trial design of switching treatments earlier ...
CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s ...
GENEVA-- (BUSINESS WIRE)--Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see ...
Corcept Therapeutics’ ALS drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate ...
On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...
Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for ...
Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results